Halozyme Therapeutic (HALO)

$69.22 -1.13 (-1.61%)
Market Cap 8.30B
Revenue (ttm) 1.40B
Net Income (ttm) 316.89M
EPS (ttm) N/A
PE Ratio 18.69
Forward PE 9.14
Profit Margin 22.69%
Debt to Equity Ratio 43.90
Volume 2,101,820
Avg Vol 2,001,808
Day's Range N/A - N/A
Shares Out 118.02M
Stochastic %K 10%
Beta 0.97
Analysts Sell
Price Target $82.75

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
Prester_John
Prester_John Feb. 25 at 5:14 PM
$HALO Nicest bunch of shorts I have encountered! WHAM down on open and then let one sell purchase higher later. Has been going on for days since earnings. I am not playing, just watching. They make just as much from the yo-yo and easier than if they try to drive it straight down.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 25 at 12:21 AM
$HALO Current Stock Price: $70.34 Contracts to trade: $70.0 HALO Mar 20 2026 Call Entry: $1.90 Exit: $2.96 ROI: 56% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
qpqpdbdb
qpqpdbdb Feb. 24 at 9:57 PM
$HALO Feels like 70 is the new 'base'. Was 60 before. Adding here and sell some on the way up to 80-90 range and holding some to sell if it blows past 90-100. Good luck everyone.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 1:01 AM
$HALO RSI: 48.64, MACD: 0.8930 Vol: 4.09, MA20: 75.45, MA50: 71.39 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Datum
Datum Feb. 20 at 5:52 PM
$HALO huh. So this company has a history of beating their annual guidance, and a history of trading at 15x multiple. Trail PE is up because of an earnings dip due to an aquisition. 2026 guidance is EPS of 8. So if they hit 8 and the multiple returns to 15, this is a $120 stock going for $71 right now.
0 · Reply
50bps
50bps Feb. 20 at 1:36 PM
$GRAL this is what happens when u loose the $HALO
0 · Reply
Sean29md
Sean29md Feb. 20 at 1:17 PM
$HALO https://seekingalpha.com/article/4871400-halozyme-delivers-record-fy2025-as-2026-sets-up-a-major-profitability-surge#scroll_comments
0 · Reply
Swahilipete
Swahilipete Feb. 19 at 7:32 PM
$HALO might be heading too 200 sma - then buy!
0 · Reply
erevnon
erevnon Feb. 19 at 4:07 PM
Wells Fargo maintains Halozyme Therapeutics $HALO at Equal-Weight and raises the price target from $65 to https://marketsblock.com/stock-upgrades-and-downgrades/
1 · Reply
Sean29md
Sean29md Feb. 19 at 2:58 PM
$HALO Halozyme has lost about $1 billion in market cap since the earnings report. Ask yourself if a one time acquisition fee which is far less than $1 billion loss in market cap is justified. Remember that an acquisition fee is not even a true loss; when you acquire an asset you gain something in return!
1 · Reply
Latest News on HALO
Halozyme to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:30 AM EST - 1 day ago

Halozyme to Participate in Upcoming Investor Conferences

Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge

Feb 18, 2026, 10:02 AM EST - 8 days ago

Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript

Feb 17, 2026, 8:24 PM EST - 8 days ago

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Feb 17, 2026, 4:01 PM EST - 9 days ago

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 10, 2026, 4:05 PM EST - 16 days ago

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth

Feb 2, 2026, 11:43 PM EST - 23 days ago

Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript

Jan 28, 2026, 12:12 PM EST - 4 weeks ago

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Jan 28, 2026, 6:30 AM EST - 4 weeks ago

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Jan 20, 2026, 4:05 PM EST - 5 weeks ago

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Jan 8, 2026, 8:00 AM EST - 7 weeks ago

Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Jan 5, 2026, 7:00 AM EST - 7 weeks ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SKYE

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Dec 18, 2025, 7:00 AM EST - 2 months ago

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)

Dec 15, 2025, 4:06 AM EST - 2 months ago

Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)

Jim Lang Elected to Halozyme's Board of Directors

Dec 8, 2025, 4:05 PM EST - 2 months ago

Jim Lang Elected to Halozyme's Board of Directors

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Dec 4, 2025, 2:22 PM EST - 3 months ago

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Dec 4, 2025, 1:26 PM EST - 3 months ago

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 3:43 PM EST - 3 months ago

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 8:30 AM EST - 3 months ago

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Nov 18, 2025, 8:50 AM EST - 3 months ago

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

Nov 17, 2025, 7:00 AM EST - 3 months ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

MRUS

The Big 3: OKLO, HALO, V

Nov 10, 2025, 1:00 PM EST - 3 months ago

The Big 3: OKLO, HALO, V

OKLO V

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Nov 7, 2025, 8:30 AM EST - 3 months ago

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 6, 2025, 11:37 PM EST - 3 months ago

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 5, 2025, 4:05 PM EST - 4 months ago

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 8:16 PM EST - 4 months ago

Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Nov 3, 2025, 4:01 PM EST - 4 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Halozyme Just Bought Its Next Decade Of Growth

Oct 23, 2025, 1:17 PM EDT - 4 months ago

Halozyme Just Bought Its Next Decade Of Growth

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Oct 21, 2025, 8:30 AM EDT - 4 months ago

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Oct 10, 2025, 8:35 AM EDT - 4 months ago

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Oct 1, 2025, 3:22 PM EDT - 5 months ago

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Oct 1, 2025, 7:16 AM EDT - 5 months ago

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Oct 1, 2025, 7:00 AM EDT - 5 months ago

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:29 AM EDT - 6 months ago

Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript

Sep 4, 2025, 5:34 PM EDT - 6 months ago

Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript

Identify Superstar Stocks Like Halozyme with Money Flows

Aug 29, 2025, 2:01 PM EDT - 6 months ago

Identify Superstar Stocks Like Halozyme with Money Flows

Halozyme to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 6 months ago

Halozyme to Participate at Upcoming Investor Conferences

Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 5:45 AM EDT - 7 months ago

Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

Aug 5, 2025, 4:01 PM EDT - 7 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Jul 23, 2025, 11:36 AM EDT - 7 months ago

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Jul 22, 2025, 8:30 AM EDT - 7 months ago

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)

Jul 14, 2025, 4:33 PM EDT - 8 months ago

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)

Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 8 months ago

Halozyme Therapeutics Added to Russell 1000® Index

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Jun 20, 2025, 1:15 PM EDT - 8 months ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 28, 2025, 8:30 AM EDT - 9 months ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 12, 2025, 10:44 AM EDT - 10 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:15 PM EDT - 10 months ago

Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

May 6, 2025, 4:01 PM EDT - 10 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 5, 2025, 5:15 PM EDT - 10 months ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

May 1, 2025, 9:06 AM EDT - 10 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

Halozyme to Report First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 8:30 AM EDT - 10 months ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Prester_John
Prester_John Feb. 25 at 5:14 PM
$HALO Nicest bunch of shorts I have encountered! WHAM down on open and then let one sell purchase higher later. Has been going on for days since earnings. I am not playing, just watching. They make just as much from the yo-yo and easier than if they try to drive it straight down.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 25 at 12:21 AM
$HALO Current Stock Price: $70.34 Contracts to trade: $70.0 HALO Mar 20 2026 Call Entry: $1.90 Exit: $2.96 ROI: 56% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
qpqpdbdb
qpqpdbdb Feb. 24 at 9:57 PM
$HALO Feels like 70 is the new 'base'. Was 60 before. Adding here and sell some on the way up to 80-90 range and holding some to sell if it blows past 90-100. Good luck everyone.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 1:01 AM
$HALO RSI: 48.64, MACD: 0.8930 Vol: 4.09, MA20: 75.45, MA50: 71.39 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Datum
Datum Feb. 20 at 5:52 PM
$HALO huh. So this company has a history of beating their annual guidance, and a history of trading at 15x multiple. Trail PE is up because of an earnings dip due to an aquisition. 2026 guidance is EPS of 8. So if they hit 8 and the multiple returns to 15, this is a $120 stock going for $71 right now.
0 · Reply
50bps
50bps Feb. 20 at 1:36 PM
$GRAL this is what happens when u loose the $HALO
0 · Reply
Sean29md
Sean29md Feb. 20 at 1:17 PM
$HALO https://seekingalpha.com/article/4871400-halozyme-delivers-record-fy2025-as-2026-sets-up-a-major-profitability-surge#scroll_comments
0 · Reply
Swahilipete
Swahilipete Feb. 19 at 7:32 PM
$HALO might be heading too 200 sma - then buy!
0 · Reply
erevnon
erevnon Feb. 19 at 4:07 PM
Wells Fargo maintains Halozyme Therapeutics $HALO at Equal-Weight and raises the price target from $65 to https://marketsblock.com/stock-upgrades-and-downgrades/
1 · Reply
Sean29md
Sean29md Feb. 19 at 2:58 PM
$HALO Halozyme has lost about $1 billion in market cap since the earnings report. Ask yourself if a one time acquisition fee which is far less than $1 billion loss in market cap is justified. Remember that an acquisition fee is not even a true loss; when you acquire an asset you gain something in return!
1 · Reply
Sean29md
Sean29md Feb. 19 at 2:21 PM
$HALO For a summary of the analyst activities since the earnings call 2 days ago see the attached screenshot from http://tipranks.com. Of course Mr. Market has a mind of its own and as mentioned earlier has a knee jerk reaction to an earnings miss even if its due to a one time acquisition fee. This is fantastic for us. Let the dumb algos and hedge funds sell more. I’d like to buy more cheaper.
0 · Reply
Sean29md
Sean29md Feb. 19 at 2:03 PM
$HALO Halozyme price target raised to $90 from $75 at Benchmark https://www.tipranks.com/news/the-fly/halozyme-price-target-raised-to-90-from-75-at-benchmark-thefly-news
0 · Reply
Sean29md
Sean29md Feb. 19 at 2:03 PM
$HALO Halozyme price target raised to $75 from $65 at Wells Fargo https://www.tipranks.com/news/the-fly/halozyme-price-target-raised-to-75-from-65-at-wells-fargo-thefly-news
0 · Reply
Bogeymakr
Bogeymakr Feb. 18 at 8:04 PM
$HALO Not going to let this breathe today... watching
0 · Reply
medguy
medguy Feb. 18 at 7:55 PM
Looking for bounce $HALO
0 · Reply
Sean29md
Sean29md Feb. 18 at 6:45 PM
$HALO $HALO Morgan Stanley just raised its price target for Halozyme from $78 to $94 See attached screenshot
1 · Reply
Sean29md
Sean29md Feb. 18 at 6:23 PM
$HALO Algos and dumb hedge funds sell first and ask questions later. This was not a miss due to a chronic elevated expenses. It was due to a one time charge for an acquisition. Smart money is scooping Halozyme up on this dip. It is a gift.
1 · Reply
Sean29md
Sean29md Feb. 18 at 6:06 PM
$HALO Algos and dumb hedge funds sell first and ask questions later. This was not a miss due to a chronic elevated expenses. It was due to a one time charge for an acquisition. Smart money is scooping halo up on this dip. It is a gift.
0 · Reply
longtermG1
longtermG1 Feb. 18 at 5:09 PM
$HALO good time to buy
0 · Reply
ZacksResearch
ZacksResearch Feb. 18 at 5:04 PM
$HALO just posted a headline that’s anything but straightforward… miss on earnings, but revenue explodes 🚀 Q4 swung to a loss on an acquisition charge, yet revenues surged 52% year over year, fueled by higher royalties and product sales — and still topped estimates. That’s a powerful top-line statement even with the bottom-line hit. Is this a short-term accounting bump or a bigger growth story unfolding? Full breakdown here 👉 https://www.zacks.com/stock/news/2871425/halozymes-q4-earnings-miss-higher-royalties-drive-yy-revenues?cid=sm-stocktwits-2-2871425-teaser-34044&ADID=SYND_STOCKTWITS_TWEET_2_2871425_TEASER_34044
0 · Reply
bullwink
bullwink Feb. 18 at 4:44 PM
$HALO why such a punishment? This market is insane!
0 · Reply
ZacksResearch
ZacksResearch Feb. 18 at 4:04 PM
$HALO Q4 earnings shocker! 📉 Reported a loss of 24 cents per share against expectations of $2.15 earnings, due to a $2.42/share impact from the Surf Bio acquisition. However, Q4 revenues surged 52% YoY, driven by product sales and royalties from Phesgo, Darzalex, and Vyvgart Hytrulo. 💰 See why it’s a mixed bag for HALO investors 👉 https://www.zacks.com/stock/news/2871425/halozymes-q4-earnings-miss-higher-royalties-drive-yy-revenues?cid=sm-stocktwits-2-2871425-body-34042&ADID=SYND_STOCKTWITS_TWEET_2_2871425_BODY_34042
0 · Reply